Monitor for finalization of commercial supply agreements with Fontaine Vitale and any regulatory approvals needed for product import into Indonesia. The Q1 2027 opening timeline provides a long lead time; near-term focus should be on Celularity's ability to resolve Nasdaq non-compliance and file delinquent 10-Qs, which are more immediate catalysts.
Price Chart
Executive Summary
Celularity highlighted progress at Fontaine Vitale, a regenerative medicine center in Bali, Indonesia, expected to open Q1 2027. The facility will offer placenta-derived stem cell therapy using Celularity's products, representing a potential new revenue stream. However, the company is in a distressed financial position with a recent $7M secured convertible note financing, Nasdaq non-compliance, and delayed quarterly filings, making this a speculative, pre-revenue opportunity with no guaranteed revenue.
Key Facts
- Fontaine Vitale grand opening expected in Q1 2027 in Sanur SEZ, Bali, Indonesia.
- Facility is developed by Genting Berhad and Indonesian partners, with strategic collaboration from Celularity.
- Celularity expects to supply placenta-derived cellular products to Fontaine Vitale, subject to final commercial arrangements and regulatory approvals.
- Company recently entered a securities purchase agreement for up to $25M in senior secured convertible notes, with an initial $7M tranche closed September 23, 2026.
- Celularity is not in compliance with Nasdaq listing rules due to late filings and low market value.
- Company has not timely filed Q1 and Q2 2026 10-Qs.
- No revenue or financial guidance provided in this press release.
Financial Impact
No financial figures disclosed; potential future revenue from Fontaine Vitale is speculative and contingent on regulatory approvals and commercial arrangements.
Risk Factors
- Fontaine Vitale opening may be delayed or cancelled; no binding commercial agreement is in place.
- Celularity's distressed financial position (secured debt, Nasdaq non-compliance, late filings) threatens its ability to operate and supply products.
- Regulatory approvals for cellular therapy import and use in Indonesia are uncertain.
- No revenue from this opportunity is guaranteed; any revenue may be delayed or lower than anticipated.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.7500 (+40.48%) |
Sep 30, 2026 26d ago | Press Release | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 29, 2026 27d ago | 8-K | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 28, 2026 28d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 28, 2026 28d ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.7500 (−43.18%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (−46.43%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.7500 (+14.81%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.7500 (−9.23%) |
Jun 30, 2026 16w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.7500 (−25.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers